DP
JAZZ icon

Diadema Partners’s Jazz Pharmaceuticals JAZZ Stock Holding History

Diadema Partners’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-105,300
Closed -$17.9M – 174
2025
Q4 		$17.9M Buy
105,300
+5,300
+5% +$813K 3.08% 7
2025
Q3 		$13.2M Buy
100,000
+50,000
+100% +$6M 3.37% 4
2025
Q2 		$5.31M Sell
50,000
-20,800
-29% -$2.26M 1.62% 20
2025
Q1 		$8.79M Buy
+70,800
New +$9.24M 2.29% 12

Other funds holding JAZZ

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Diadema Partners's JAZZ Position: Q1 2026 in Review

Diadema Partners opened a new position in Jazz Pharmaceuticals (JAZZ) in Q1 2026: 54,755 shares worth $10.4M. The stake represents 1.76% of the portfolio and ranks #18 among its holdings. This is a return to the name: Diadema Partners previously reported a position in JAZZ as recently as Q3 2025.

Diadema Partners first reported a position in JAZZ in Q4 2024 and has held it in 5 quarters since. The position peaked at $11.1M in Q2 2025. 571 funds tracked by Wall St. Rank hold JAZZ as of Q1 2026.

  • Diadema Partners held 54,755 shares of Jazz Pharmaceuticals worth $10.4M as of Q1 2026.
  • Jazz Pharmaceuticals was a new Diadema Partners position in Q1 2026.
  • Jazz Pharmaceuticals made up 1.76% of Diadema Partners's portfolio in Q1 2026, its #18 holding.
  • Diadema Partners first reported a position in Jazz Pharmaceuticals in Q4 2024 and has held it in 5 quarters since.
  • Diadema Partners's Jazz Pharmaceuticals position peaked at $11.1M in Q2 2025.
  • 571 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2026.

Based on Diadema Partners's 13F filing for Q1 2026, filed 15 May 2026.